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ABSTRACT
Background: In recent years, several genomic regions have been robustly associated with coronary artery disease
(CAD) in different genome-wide association studies (GWASs) conducted mainly in people of European descent.
These kinds of data are lacking in African populations, even though heart diseases are a major cause of premature
death and disability.
Methods: Here, 384 single nucleotide polymorphisms (SNPs) in the top four CAD risk regions (1p13, 1q41, 9p21,
and 10q11) were genotyped in 274 case-control samples from Morocco and Tunisia, with the aim of analyzing for the
ﬁrst time if the associations found in European populations were transferable to North Africans.
Results: The results indicate that, as in Europe, these four genetic regions are also important for CAD risk in North
Africa. However, the individual SNPs associated with CAD in Africa are different from those identiﬁed in Europe in
most cases (1p13, 1q41, and 9p21). Moreover, the seven risk variants identiﬁed in North Africans are efﬁcient in
discriminating between cases and controls in North African populations, but not in European populations.
Conclusions: This study indicates a disparity in markers associated to CAD susceptibility between North Africans
and Europeans that may be related to population differences in the chromosomal architecture of these risk regions.
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INTRODUCTION
Cardiovascular disease (CVD) continues to be the leading
cause of mortality and morbidity in Western populations.1
According to World Health Organization data, 17.3 million
people died from CVD in 2008, representing 30% of all
global deaths (http://www.who.int/cardiovascular_diseases/
about_cvd/en/). In North Africa and the Middle East, non-
communicable diseases are an increasingly prevalent cause of
premature death and disability (http://www.who.int/whr/2013/
report/en/). For example, ischemic heart disease and stroke
have increased by 44% and 35%, respectively, during the last
20 years.
The most common type of heart disease is coronary artery
disease (CAD), which is a paradigm of complex disease,
where environmental, lifestyle, and genetic factors interact
to determine the clinical phenotype.2 In recent years, several
genetic variants robustly associated with CAD have been
detected, mainly in people of European descent (96%),3
through genome-wide association studies (GWASs).
Previous surveys in non-European populations have
suggested that markers associated in one population may not
always easily translate to other populations. Associations
found in Europeans must be investigated in other ethnic
groups3 to assess the replicability of association signals or to
detect new population-speciﬁc risk markers. For example,
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three variants in the major susceptibility gene (NOD2) for
Crohn’s disease were associated with susceptibility in
Europeans.4,5 However, the same variants did not show
evidence of association in Morocco and Tunisia.6,7 Likewise,
the genetic susceptibility alleles for glaucoma in European
populations do not seem to play a substantial role in
populations of African ancestry.8 On the contrary, a recent
study afﬁrmed that Europeans and North Africans share the
same 13 risk markers for type 2 diabetes.9 For the most studied
CAD risk regions, 9p21, the lack of replication of European
association signals in African samples was previously reported
for coronary artery calciﬁcation10 and ischemic stroke.11 These
differences in association signals between different population
groups raise intriguing questions, and an increase in the
number of epidemiological studies in different populations is
required not only to validate the known risk loci, but also to
identify new population-speciﬁc susceptibility variants.
In this way, the present study deals with a ﬁne analysis of
the four most validated CAD risk regions, 1p13, 1q41, 9p21,
and 10q11, which are included among the labeled “top 12
golden loci”,2 in a novel set of case-control samples from
North Africa. The main goal is to check the level (genomic
regions and/or individual sites) to which the CAD associations
previously found in Europe may also be transferable to North
Africa, speciﬁcally to people of Tunisian and Moroccan
origin. To accomplish this goal, 384 single nucleotide
polymorphism (SNPs) on those four genomic regions were
genotyped in case-control samples from North Africa. The
associations and trends detected in North African samples
were compared with available data from southern Europe.
Finally, the combined effects (risk score) of the associated
markers found in North Africa, and their ability to
discriminate between cases and controls, were assessed.
MATERIALS AND METHODS
Samples
A total of 142 cases and 132 controls from Morocco and
Tunisia (52% males) were analyzed in the present study. The
Moroccan samples consisted of 72 subjects from the area of
Casablanca, along with 51 controls from the Doukkala-Abda
region in west-central Morocco. The Tunisian case samples
included 70 patients treated at the Department of Cardiology
of the University Hospital Fattouma Bourguiba (Monastir,
Tunisia). As a control group, 81 unrelated individuals,
free from any CAD or related disorders, were randomly
selected from the same large geographical area to which the
patients belonged (the center of Tunisia). In both countries,
CAD patients were diagnosed for ischemic heart disease
complicated by myocardial infarction (MI), which was
conﬁrmed by electrocardiography and coronary angiography.
All participants provided written informed consent, and
the study was approved by the Ethics Committee of the
University of Barcelona.
For comparative purposes, we used data from two southern
European matched case-control samples (Milan, ATVB,
in northern Italy, and Girona, Regicor, in north-eastern
Spain) from the Myocardial Infarction Genetics (MIGen)
Consortium,12 which was accessed through the database of
Genotypes and Phenotypes (dbGAP; http://www.ncbi.nlm.
nih.gov/gap). Baseline characteristics of the samples used in
the study are shown in Table 1.
Polymorphisms and genotyping
Genomic DNA was extracted from blood cells using a Blood
Midi kit (Omega Biotek, Norcross, GA, USA) in accordance
with the manufacturer’s procedures. DNA samples were
genotyped for a set of 384 SNPs using a Custom GoldenGate
Panel (Illumina Inc., San Diego, CA, USA). Out of the 384
SNPs, 61 are located in the 1p13.3 chromosomal region,
which spans 150 kb and includes the CELSR2, PSRC1,
MYBPHL, and SORT1 genes; 38 SNPs are in 1q41, which
spans 100 kb and includes the TAF1A,MIA3, and AIDA genes;
159 SNPs are in 9p21, which spans 300 kb and comprises the
CDKN2A and CDKN2B genes; and ﬁnally, 126 SNPs are
in the 10q11 chromosomal region, which spans 200 kb and
includes the CXCL12 gene.
SNPs were selected as a representative set of the common
variation in the four genomic regions according to the
following criteria: i) average coverage of 1 SNP every
1.5 kb; ii) minor allele frequency (MAF) higher than 0.05 in
European (CEU) HapMap populations; iii) avoiding markers
in tight linkage disequilibrium (LD) (r2 > 0.8); and iv) giving
priority to markers previously reported as associated with
CAD.13 These criteria were applied to give preference to tag
SNPs.
Genotype data coming from the MIGen samples were
generated in the corresponding original projects using the
Affymetrix 6.0 GeneChip (Affymetrix, Inc., Santa Clara, CA,
USA).12
Statistical analyses
Genotyping rate per SNP and individual, Hardy-Weinberg
equilibrium (HWE), cryptic relatedness, MAF, and LD were
checked using PLINK version 1.07 (Center for Human
Genetic Research, Massachusetts General Hospital, and the
Broad Institute of Harvard & Massachusetts Institute of
Technology, Cambridge, MA, USA).14 Individuals with more
than 5% of missing genotypes were excluded. SNPs with
Table 1. Baseline characteristics of the samples
Morocco Tunisia Milan Girona
N Cases 72 70 1693 312
Controls 51 81 1668 317
Mean Age (SD) Cases 56.5 (10.8) 40.3 (10.1) 39.4 (4.9) 45.9 (5.9)
Controls 23.0 (1.5) 23.8 (3.4) 39.3 (5.0) 46.0 (5.6)
% Males Cases 68.0 55.7 88.3 79.5
Controls 54.9 29.6 88.3 78.5
SD, standard deviation.
Coronary Artery Disease in North Africa2
J Epidemiol 2016
genotyping rate lower than 0.95 or with a MAF lower than 5%
were also removed from the analyses.
In order to have the same genetic information, several
SNPs not originally genotyped in MIGen samples were
imputed simultaneously for cases and controls using MACH
1.0 software (Department of Biostatistics and Center for
Statistical Genetics, University of Michigan, Ann Arbor, MI,
USA).15 Phased chromosomes from the Tuscan (TSI) samples
from the 1000 Genomes Project16 were used as a reference
panel. A standard single-step imputation approach, with 200
rounds of Markov chain iterations, was used to estimate the
crossover maps, error rate maps, and all missing genotypes.
Associations were tested by logistic-regression models
adjusted for gender. Permutation tests (1000 permutations)
were applied to assess the statistical signiﬁcance (P ≤ 0.05)
of the regression models. Permutation procedures provide a
computationally intensive approach to empirically generating
signiﬁcance levels. Associations and permutations were
calculated using PLINK.14 In the case of the European
case-control samples, logistic-regression models adjusted for
gender were calculated using both the allelic dosage approach,
which accounts for imputation uncertainty, and the most
likely genotype approach. The mach2dat software version
119 (Department of Biostatistics and Center for Statistical
Genetics, University of Michigan)17 was used for the dosage
approach. Statistical power of the North African samples was
checked by the QUANTO software version 1.2 (University of
Southern California, Los Angeles, CA, USA).18
Haplotype structure and LD pattern analyses were
performed by HaploView version 4.2 (Broad Institute)19
using the algorithm proposed by Gabriel et al.20 Monte Carlo
statistical signiﬁcance was assessed for each chromosomal
region in order to evaluate differences between populations
in regional LD structure based on the r2. This analysis was
carried out using 100 random individuals for each different
population group (North Africa and southern Europe) using
VarLD software version 1.0 (National University of Singapore,
Singapore).21
Genetic differentiation between Moroccans and Tunisians
was calculated by means of a Fisher’s exact probability test
through Genepop version 4.2 (Laboratiore de Genetique et
Environment, Montpellier, France).22
Considering that sample sizes of cases and controls from
Morocco and Tunisia were not very large, three random effect
meta-analyses were performed to provide pooled allelic odd
ratios (ORs) with: i) samples from North Africa, ii) samples
from southern Europe, and iii) both populations together,
paying special attention to markers found as signiﬁcantly
associated in North Africa. Besides the statistical signiﬁcance,
an association was considered positive if the distribution
pattern of the risk allele frequency was similar in the different
case-control groups. The meta-analyses and the degree of
heterogeneity (I2) in the different groups analyzed were
calculated by means of the Metafor R package (R Foundation
for Statistical Computing, Vienna, Austria).23 The I2 index
describes the percentage of total variation across studies due
to true heterogeneity rather than chance. A value of 0%
indicates no observed heterogeneity, and larger values show
increasing heterogeneity.
The joint effect of multiple risk SNPs (risk score) was
explored by a logistic-regression model that included the
number of risk alleles as an independent variable. The increase
in risk was quantiﬁed by adding supplementary risk alleles
according to results of the North African meta-analysis. In this
case, homozygotes for the protective allele were coded as 0,
heterozygotes as 1, and homozygotes for the risk allele were
coded as 2. Additionally, the overall score (ie, the number
of risk alleles) was calculated for each individual and
compared between cases and controls. The ability of this
model to discriminate between patients and healthy controls
was evaluated through receiver operating characteristic
(ROC) curves using logistic-regression models. The area
under the ROC curve (AUC) was calculated as a measure of
discriminative accuracy. The risk score and the ROC curve
were calculated using the PredictABEL R package24 (R
Foundation for Statistical Computing).
A ﬂowchart of all the analyses performed is included as
eFigure 1.
RESULTS
Genotyping, quality control, and imputation
According to the above criteria, the initial design included 1
SNP every 1.8Kb, and the genotyping rate for the 384 SNPs
initially tested was 95.7%. However, 15 SNPs were not
successfully genotyped, 1 SNP showed a signiﬁcant departure
from Hardy-Weinberg equilibrium after Bonferroni correction,
and 19 SNPs failed the frequency test (MAF <0.05); these
were excluded from the study. Thus, a total of 349 markers
were included in the analyses after quality control: 57 SNPs in
1p13, 36 in 1q41, 148 in 9p21, and 108 in 10q11 (a detailed
list can be found in eTable 1). Moreover, one individual was
removed for low genotyping rate (>5% of missing genotypes).
The statistical power of the Moroccan and Tunisian samples
was low when the two samples were analyzed separately. For
example, a SNP with a MAF of 0.25 had a statistical power of
37.7% and 45.8% for Moroccans and Tunisians, respectively,
to detect an OR of 1.6 with a type I error rate of 0.05.
However, when we considered both samples together, the
statistical power substantially increased to 70.1% under the
same assumptions as above.
Concerning comparison data from MIGen project,
genotyping status and imputation quality index (r2) are
presented in eTable 1. One hundred and seventy-four out of
the 349 SNPs were imputed, and only 14 of them showed an
imputation quality lower than 0.3 in at least one case-control
sample. Therefore, 335 SNPs were considered consistent for
this analytical epidemiologic analysis. Most of the imputed
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SNPs (79%) showed high accuracy (r2 > 0.75), indicating
good quality of the imputation performed. After quality control
per individual, a total of 4979 case-control samples from
Europe were used for comparisons, with 3352 individuals
from the ATVB (Italy) and 627 from the Regicor (Spain)
studies.
Marker association analyses
A total of 5 SNPs were associated with CAD in Morocco (2 in
the 1p13 chromosomal region and 1 in each one of the other
three regions), whereas 26 were associated with CAD in
Tunisia (5 in the 1p13 region, 7 in the 9p21, and 14 in the
10q11 region). Logistic regression results and genetic effects
of these SNPs are shown in eTable 2. None of these SNPs was
associated independently in Morocco and Tunisia, but most of
them (24 out of 31) showed the same trends in the two African
populations (ie, OR values higher or lower than 1).
Preliminary comparisons of the results in North Africa with
the two European samples from the MIGen Consortium
pointed out a low replicability of association signals between
both groups of populations (eTable 2). For example, 12 out
of 26 of the SNPs associated in the Tunisian sample were
also associated in the ATVB study, but 4 of them showed an
opposite effect.
An exact test indicated consistent genetic similarity between
the two North African countries for both cases (P = 0.248) and
controls (P = 0.927). In the meta-analysis of North African
samples, seven SNPs showed signiﬁcant associations with a
remarkably low heterogeneity (I2 = 0%) (Table 2), with two
corresponding to the 9p21 region and ﬁve corresponding to the
10q11 region. All of these SNPs were located in intergenic
regions. In the 1p13 and 1q41 regions, no association was
detected.
The potential population speciﬁcity of the seven risk
variants detected in North Africa was assessed by com-
parison with the results of the meta-analyses carried out in the
European populations. None of these seven SNPs showed
signiﬁcant associations in southern European populations
(Table 2). The heterogeneity among the southern European
samples was remarkably low, except for the rs800314 marker
(I2 = 51%).
The third meta-analysis performed using the North Africans
and the southern Europeans case-control samples did not
show signiﬁcant associations for the seven SNPs previously
identiﬁed in the African meta-analyses. The heterogeneity
among African and European samples was medium to high
(I2 from 21% to 74%), except for the rs7918568 marker
(I2 = 0%) (Table 2).
Haplotype analyses
Haplotype structure was analyzed to better understand the
patterns of associations observed in these two different
populations groups. As expected, different patterns of
haplotype blocks were identiﬁed in North Africa and
southern Europe (LD patterns and haplotype block structure
are plotted in eFigure 2A, eFigure 2B, eFigure 2C, and
eFigure 2D). In general, a higher number of haplotype
blocks in North Africans compared to southern Europeans
were observed in all four chromosomal regions: 6 versus 2
blocks in 1p13; 4 versus 2 in 1q41; 23 versus 21 in 9p21; and
12 versus 10 in 10q11. The two population groups showed
statistically signiﬁcant differences in LD patterns for all
four chromosomal regions (P < 0.001 for the 1p13 and 9p21
regions, and P < 0.05 for the 1q41 and 10q11 genomic
regions). The comparison of the haplotype blocks that included
the seven African risk SNPs indicated that these risk variants
are not located in the same haplotype blocks in African and
European individuals (eFigure 2C and eFigure 2D).
Risk scores
The genomic risk-score was calculated using the information
of SNPs associated in the North African meta-analysis. After
applying LD pruning criteria in both European and North
African samples (r2 < 0.4), six SNPs (making possible risk
scores from 0 to 12 risk alleles) were considered in the analysis
(eTable 3). In North Africa, the distribution of the risk score
between patients and healthy individuals showed signiﬁcant
differences (Figure 1). A total of 32% of cases carried 6 risk
alleles, whereas only 26% of controls showed the same amount
of risk alleles. The risk score applied in North Africa showed
a remarkable ability to discriminate between individuals with
and without the disease (AUC = 0.63; 95% CI, 0.56–0.69)
Table 2. Results of the three meta-analyses performed in North Africans, South Europeans, and merging both continental
groups
CHR BP SNP
North Africa South Europe All groups
P OR CI I2 P OR CI I2 P OR CI I2
9 22136489 rs1333051 0.016 0.470 (0.250–0.870) 0 0.726 1.020 (0.900–1.160) 0 0.410 0.840 (0.560–1.260) 74
9 22191189 rs828576 0.038 1.530 (1.020–2.290) 0 0.185 0.940 (0.860–1.030) 0 0.784 1.030 (0.850–1.230) 39
10 44730995 rs7907961 0.019 1.870 (1.110–3.140) 0 0.851 1.010 (0.910–1.120) 0 0.376 1.070 (0.920–1.260) 21
10 44786364 rs800314 0.013 0.380 (0.170–0.810) 0 0.410 0.870 (0.630–1.210) 51 0.152 0.740 (0.490–1.120) 56
10 44855663 rs266105 0.007 2.180 (1.240–3.850) 0 0.729 0.980 (0.860–1.110) 0 0.245 1.260 (0.850–1.860) 70
10 44856370 rs266103 0.019 1.890 (1.110–3.220) 0 0.601 0.970 (0.850–1.100) 0 0.369 1.150 (0.850–1.54) 53
10 44861220 rs7918568 0.047 1.600 (1.010–2.530) 0 0.300 1.060 (0.950–1.180) 0 0.144 1.080 (0.970–1.200) 0
CI, conﬁdence interval; I2, index to quantify the % of true heterogeneity (total heterogeneity/total variability); OR, odds ratio.
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(Figure 2). In addition, the risk for CAD in North Africa
increases with the number of risk alleles included in the risk
score. The susceptibility to develop CAD in North Africans
shows a signiﬁcant value from the group that had 6 risk alleles
(P = 0.04) and, as the number of risk alleles increases, the OR
value also increases, reaching a maximum for the individuals
with 8–12 risk alleles (Figure 3). Comparatively, this risk
score had remarkably lower ability to predict CAD risk in
southern Europeans than in North Africans (AUC = 0.52; 95%
CI, 0.50–0.54) (eFigure 3).
DISCUSSION
This study provides novel genetic data of epidemiological
interest in North Africa. The genomic variation of four CAD
risk regions (1p13, 1q41, 9p21, and 10q11) was analyzed
through the genotyping of 384 SNPs in two North African
case-control samples, speciﬁcally from Morocco and Tunisia.
Figure 1. Distribution of North African individuals according to the number of risk alleles in the sample of cases and
controls analyzed.
Figure 2. Receiver operating characteristic (ROC) curves in North Africa.
AUC, Area Under the ROC Curve with 95% conﬁdence interval.
Figure 3. Logarithm of the odds ratios with 95%
conﬁdence interval for CAD (adjusted by
gender) in North African individuals carrying
increasing numbers of risk alleles.
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Previous studies of these genomic regions were based on
populations of European descent. To the best of our
knowledge, these are the ﬁrst results in populations from
Africa. Consequently, this study aimed to assess whether
ﬁndings about CAD risk variants in European populations can
also be extended to North Africans.
We found signiﬁcant association signals in the four
genomic regions analyzed also in Moroccan and Tunisian
samples. However, in the meta-analyses performed with
the African case-control samples, only the 9p21 and 10q11
regions showed association signals. None of the North African
risk SNPs showed association in European samples. In
addition, the calculated risk model had a remarkable ability
to discriminate cases and controls in Africa (AUC = 0.63) but
not in Europe (AUC = 0.52). These arguments suggest the
existence of continental-speciﬁc CAD risk variants in these
chromosomal regions.
Continent-speciﬁc risk markers within global risk
regions
Among the several CAD risk loci identiﬁed so far, the 9p21
locus has a prominent position because of the impressive
robustness of the association results.25–27 In the North African
meta-analysis, two SNPs in this genomic region showed
association with CAD. A detailed analysis of the literature
revealed that the rs1333051 marker was previously associated
with type 2 diabetes in Mexican Americans.28 The 10q11
genomic region shows the highest number of associated SNPs
in North Africa (5 out of 7 of the associated SNPs). None
of these ﬁve SNPs was found to be associated with CAD in
previous studies.
Regarding the logistic association performed in the four
populations analyzed (Morocco, Tunisia, Italy, and Spain),
the associated SNPs were not the same across populations,
even though association signals were present in all of the
regions studied. Of note, some associated SNPs are close to
SNPs associated in other populations, while other SNPs are
population-speciﬁc (ie, physically distant or not in LD with
SNPs associated in other populations).
The number of SNPs associated with risk of CAD in
southern Europe is considerably larger than in North Africa,
as expected from the much larger sample size (and statistical
power) of the European dataset. The ability of the limited
sample size to reach the signiﬁcance threshold of the North
African samples may be the cause of the low number of
associations found in Africa and the lack of replication in
African samples of most associations found in Europe. Still,
the risk SNPs found in North Africa but not replicated in
Europe underline the possible role of the genomic architecture
in these results. Statistical power calculations indicate reduced
power of the North African case-control samples to detect
small genetic effects, but adequate power to detect a risk with
an OR ≥1.6. Although sample size biases cannot be fully
discounted, the SNPs associated in Africa but not in Europe
show an adequate statistical consistency according to the
permutation tests performed.
The signiﬁcant differences (P < 0.05) in the LD and the
haplotype patterns in the two population groups (eFigure 2A,
eFigure 2B, eFigure 2C, and eFigure 2D) conﬁrm the hetero-
geneity in the genomic structure between North Africans and
Europeans. This general trend of lower haplotype diversities
and higher LD values when the geographic distance from
Africa increases has been previously observed.29,30 Further,
the haplotype blocks containing risk SNPs differ between
North Africa and southern Europe. This situation is especially
evident in the 10q11 region, where three out of the ﬁve
associated SNPs are not located in any block in North Africa,
while in Europe only one of these SNPs is not located in a
block (eFigure 2D). Differences in allele frequency and LD
patterns may be related to the observed differences in the
association tests. Higher LD (illustrated by the different
number of haplotype blocks) in populations of European
origin compared to Africans reduces the likelihood of
ﬁnding a substantial number of associated SNPs in North
Africa.31 African populations are genetically more diverse
than European and Asian populations, a ﬁnding that is in
agreement with the Recent-African-Origin hypothesis.32
Consequently, replication studies across European popula-
tions have been largely successful because of the general
genetic similarity across European populations. A failure to
replicate an association signal in Africa may be inﬂuenced
by variations in LD patterns between European and African
populations.31 Low levels of LD reduce the correlation among
casual variants and nearby SNPs. As a consequence, the
probability of detecting association signals is lower among
Africans than in Europeans if the causal variants are not
assayed directly.
The potential existence of ethnicity-speciﬁc CAD risk
markers is not an isolated case; rather, such risk markers are
common in complex diseases. A recent study detected
signiﬁcant differences in association signals among African
and European populations screening the catalog of all
published GWAS curated at the National Human Genome
Research Institute website.33 This work stressed a modest
correlation in the risk allele frequencies between Europeans
and Africans. The point estimates of risk were opposite in
direction or differed more than 2-fold in 79% of the
comparisons between European and African groups. Along
with this fact, the under-representation of non-European
population in GWAS suggests the need to extend epide-
miological studies to a much broader ensemble of populations,
including ethnic minorities.3
Conclusion
This study shows that in North African populations, as in
European populations, the regions 1p13, 1q41, 9p21, and
10q11 contain genetic risk variants associated with CAD.
However, Europeans and North Africans do not always share
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the same risk variants. The differences obtained in CAD risk
variants between Europeans and North Africans suggest that
ﬁndings from one population cannot be directly applied to
populations from other continents. That is, differences in the
genomic architecture due to different demographic histories
should be taken into account in epidemiological studies of
complex disorders. This preliminary evidence from four CAD
risk genomic regions in North African populations needs to be
extended in additional larger analyses.
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